Bruker AXS Announces Agreement to Acquire the Princeton Gamma-Tech (PGT) X-Ray Microanalysis Business
October 26 2005 - 6:00AM
Business Wire
Bruker AXS Inc. today announced an agreement to acquire the PGT
X-ray microanalysis business with annual revenues of $5-6 million
from Princeton Gamma-Tech Instruments, Inc. The terms of the
transaction were not disclosed, and the acquisition is expected to
close in the fourth quarter of 2005. On October 14, 2005, Bruker
AXS had announced an agreement to acquire Roentec AG, an X-ray
microanalysis company based in Berlin, Germany. After the closing
of both transactions, Roentec AG and the PGT Microanalysis Business
will be combined into the new 'Bruker AXS Microanalysis Group',
which will focus on the $150 million per annum global X-ray
microanalysis market. The PGT microanalysis business features an
excellent X-ray microanalysis product line, with advanced
technology, and many outstanding data acquisition and analysis
software features. Moreover, the PGT microanalysis business has
extensive distribution and service capabilities in the United
States, the United Kingdom and France. Roentec, a broad-based X-ray
instrumentation company, has a technically leading microanalysis
product line with outstanding detector technology and ultra-fast
acquisition electronics. Roentec also has developed unique mobile
systems for the XRF microanalysis of works of art, as well as novel
transportable Total Reflection X-ray Fluorescence (TXRF) systems
for elemental trace analysis in liquids, e.g. for environmental or
beverage analysis. Roentec has established good distribution and
service capabilities in continental Europe, as well as in selected
other countries. Roger Durst, Ph.D., Bruker AXS Executive Vice
President, commented: "Roentec and PGT both have excellent
technology and products, and both have a strong customer base in
complementary geographical markets. However, both companies also
have been distribution-limited and at a size disadvantage relative
to their larger competitors. We believe that their combined product
line and software, further enhanced by additional technologies from
Bruker AXS, can offer leading capabilities, as well as extensive
service and support coverage to X-ray microanalysis customers
anywhere in the world." Background on X-Ray Microanalysis Market
The X-ray microanalysis market consists of X-ray accessories for
scanning and transmission electron microscopes, as well as of
stand-alone micro X-ray fluorescence (XRF) spectrometers. X-ray
microanalysis is considered to be one of the faster growing
segments of the overall X-ray analysis market. Applications of
X-ray microanalysis include nanotechnology and advanced materials
research, as well as materials analysis and quality control, with
customers in industry, academia and government research facilities.
Bruker AXS, a technology and market leader in X-ray diffraction
(XRD) systems for advanced materials and nanotechnology research,
in X-ray single crystal diffraction (SCD crystallography) systems
for small molecule and protein 3D structural analysis, and in X-ray
fluorescence (XRF) elemental analysis for a variety of materials
analysis and quality control applications, so far has not
participated in the X-ray microanalysis market segment. For more
information, please visit www.bruker-axs.com. ABOUT BRUKER
BIOSCIENCES (NASDAQ: BRKR) Bruker BioSciences Corporation,
headquartered in Billerica, Massachusetts, is the publicly traded
parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker
AXS is a leading developer and provider of life science and
advanced materials research tools based on X-ray technology. Bruker
Daltonics is a leading developer and provider of innovative life
science tools based on mass spectrometry. For more information,
please visit www.bruker-biosciences.com. CAUTIONARY STATEMENT Any
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995. Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of
conditions, technological approaches, product development, market
acceptance, cost and pricing of the Company's products, changes in
governmental regulations, capital spending and government funding
policies, FDA and other regulatory approvals to the extent
applicable, competition, the intellectual property of others,
patent protection and litigation. These and other factors are
identified and described in more detail in our filings with the
SEC, including, without limitation, our annual report on Form 10-K
for the year ended December 31, 2004, our most recent quarterly
reports on Form 10-Q and our current reports on Form 8-K. We
disclaim any intent or obligation to update these forward-looking
statements.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024